The latest announcement is out from Beximco Pharmaceuticals Limited Sponsored GDR RegS ( (GB:BXP) ).
Beximco Pharmaceuticals Limited has announced an update regarding the Bangladesh Securities and Exchange Commission’s (BSEC) proposal to appoint nine new independent non-executive directors to its board. The Supreme Court of Bangladesh’s Appellate Division has overturned a previous High Court Stay Order, directing the High Court to resolve the company’s writ petition by March 19, 2025. The final decision on the appointments will depend on the outcome of the High Court proceedings and due diligence for UK regulatory purposes. This development could impact the company’s governance structure and its compliance with regulatory requirements.
More about Beximco Pharmaceuticals Limited Sponsored GDR RegS
Beximco Pharmaceuticals Limited, based in Bangladesh, is a leading manufacturer and exporter of generic medicines. Established in 1976, the company offers a wide range of pharmaceutical products, including tablets, capsules, and injectables. It also provides contract manufacturing services for multinational and global generic pharmaceutical companies. Beximco Pharma’s manufacturing facilities are certified by regulatory authorities in the USA, Europe, and other regions, and the company operates in over 50 countries with more than 6,000 employees.
YTD Price Performance: -1.28%
Average Trading Volume: 33,754
Technical Sentiment Consensus Rating: Buy
For detailed information about BXP stock, go to TipRanks’ Stock Analysis page.